Anuh Pharma Limited reported a 16.65% year-on-year increase in revenue from operations to ₹771.66 crore for the financial year ended March 31, 2026. The company successfully completed USFDA and EU GMP inspections during the year, reinforcing its commitment to global quality standards. Despite the revenue growth, net profit for the year declined by 13.32% to ₹41.05 crore, impacted by increased expenses and other income fluctuations.

For the quarter ended March 31, 2026, revenue stood at ₹202.12 crore, compared to ₹197.18 crore in the preceding quarter. The company achieved record production volumes of 1,733 metric tonnes in FY26, an increase of 24.99%, supported by strong plant utilization. EBITDA for the year was ₹66.08 crore, with a margin of 8.56%, while quarterly EBITDA improved to ₹18.63 crore with a margin of 9.22%.

Financial Performance

The following table outlines the key financial metrics for the quarter and full year:

Operational Highlights

The company derived approximately 46% of its revenues from exports in FY26, serving 360 customers across over 72 countries, including Europe, Mexico, and South Africa. Anuh Pharma is one of the largest manufacturers of Macrolides and Anti-TB products in India. The company enhanced its production capacity from 2,200 MTPA to 2,400 MTPA in 2025. Management anticipates a steady growth rate of 15-20% per annum driven by volume expansions and strategic market diversification.

Anuh Pharma Limited disclosed that its promoters and promoter group collectively held 7,19,56,044 equity shares as on March 31, 2026. Bharat Nemchand Shah, filing on behalf of all promoters, promoter group, and persons acting in concert, confirmed that no encumbrance was created on these shares during the financial year ended March 31, 2026. The filing was submitted to BSE Limited and National Stock Exchange of India Limited in compliance with Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

The detailed shareholding pattern of the promoter group was provided in Annexure-A to the disclosure. The list includes 37 entities ranging from individuals to Hindu Undivided Families (HUFs) and Limited Liability Partnerships (LLPs). Bharti Bipin Shah emerged as the largest holder within the group with 1,94,74,800 shares, followed by Prafulla Lalit Shah with 1,44,99,132 shares. Bipin Nemchand Shah, in his individual capacity, held 62,21,720 shares, while his HUF held 84,94,200 shares.

Shareholding Details

The following table outlines the shareholding distribution among the key members of the promoter and promoter group:

The disclosure confirms that the total shareholding of the promoter and promoter group stands at 7,19,56,044 equity shares. The document was signed by Bharat Nemchand Shah, Promoter and Director, on April 06, 2026. A copy of the disclosure was also marked to the Audit Committee of Anuh Pharma Limited.